Infantile spasm treatment market
Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
- Jan 2019
- CMI2453
- 150 Pages
- Excel & Pdf
- Pharmaceutical
Global Infantile Spasm Treatment Market – Rich Product Pipeline for Rare Disease
Infantile spasm treatment play a major role in modern healthcare, as they are used for the treatment of seizures of an epilepsy syndrome in infants usually below 1 year.
The global infantile spasm treatment market size was valued at US$ 111.1 million in 2017 and is expected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026).
Figure 1. Global Infantile Spasm Treatment Market Value (US$ Mn), by Region, 2017
Source: Coherent Market Insights Analysis (2018)
Increasing government initiatives for treatment of rare diseases is expected to propel growth of the infantile spasm treatment market
Infantile spasm, also called as west syndrome, is a rare disorder that affects children below 1 year age. Seizures in children often appear as normal hiccups or body movement, and parents are unaware about the presence of this disease in their kid. Therefore, to tackle this challenge, various governments and organizations are initiating programs to educate people about the disease. The government of China published a comprehensive list of rare diseases in 2018, in order to better identify the patients affected by rare disease and provide treatment for the same. Moreover, such initiatives will help to speed up the drug development process for rare diseases.
Increasing birth rate could result in high prevalence of infantile spasm, which is expected to drive growth of the infantile spasms treatment market over the forecast period.
However, high cost of treatment, lack of proper diagnosis of infantile spasm, and stringent regulations for drug approval are some of the factors hindering the market growth. For instance, Acthar, which is a corticotropin branded product from Mallinckrodt pharmaceutical, costs around US$ 125,000 per patient, i.e. US$ 28,000 per dose
Figure 2. Global Infantile Spasm Treatment Market Share (%), by Product Type, 2018 and 2026
Source: Coherent Market Insights Analysis (2018)
Increasing adoption of infantile spasms treatment procedure in North America is expected to bolster the market growth
North America holds dominant position in the global infantile spasm treatment market, owing to high adoption of infantile spasms treatment procedures and large scale research and development activities in this region. For instance, INSYS Therapeutics developed Cannabidiol in October 2012, Oral Solution for infantile spasm, which is under phase III clinical trial. The reoccurrence of infantile spasm is a major factor that boosts the market growth.
Increasing prevalence of central nervous system (CNS) infection can develop infantile spasm which in turn is expected to boost the market growth. In July 2012, the National Center for Biotechnology Information (NCBI) report stated that around 50% of infantile spasm cases in the U.S. have a prenatal cause, including central nervous system infection, intrauterine insults, neurologic disorders such as tuberous sclerosis complex (TSC), and genetic syndrome.
Moreover, approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) that helps in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth.
Key Players
Major players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Route Of Administration
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Diagnostic Algorithm For Infantile Spasms
- Treatment Options In Infantile Spasms
- Relapse In Infantile Spasms
- Pipeline Analysis
- Organizations Providing Infantile Spasms Information
- Challenges Faced By Rare Disease Drug Discovery Programs
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Global Infantile Spasm Treatment Market, By Product Type, 2018 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Adrenocorticotropic Hormone (ACTH)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Vigabatrin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Global Infantile Spasm Treatment Market, By Route of Administration, 2018 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Global Infantile Spasm Treatment Market, By Region, 201 – 2026, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Route Of Administration, 2016 – 2026, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- H. Lundbeck A/S
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mallinckrodt Pharmaceuticals
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Catalyst Pharmaceuticals
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GW Pharmaceuticals plc
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Retrophin, Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Valerion Therapeutics
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Orphelia Pharma SA
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Insys Therapeutics, Inc.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Anavex Life Sciences Corp.
- Company Overview
- Product Type Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 39 market data tables and 29 figures on "Infantile Spasm Treatment Market - Global forecast to 2026”.